Articles

91. Case Study: Product Development Of An Inhaled Protein 4/9/2010

    A small biotechnology company in the United States turned to Aptuit to support the development of their inhaled respiratory product. They had added confidence that their limited in-house capability would benefit from Aptuit’s substantial experience and capabilities in respiratory science projects, fulfilling their need for first-in-class capabilities in manufacturing, clinical packaging and logistics, bio-analytics and respiratory analytics. By Aptuit, Inc.

92. Product Development Of An Inhaled Protein 4/9/2010
    A small biotechnology company in the United States turned to Aptuit to support the development of their inhaled respiratory product. They had added confidence that their limited in-house capability would benefit from Aptuit’s substantial experience and capabilities in respiratory science projects, fulfilling their need for first-in-class capabilities in manufacturing, clinical packaging and logistics, bio-analytics and respiratory analytics. By Aptuit, Inc.
93. Case Study: Controlled Drug Handling 4/9/2010
    A midsize pharmaceutical company came to Aptuit to work through the complexities of exporting a controlled substance manufactured in the United States and an EU-sourced comparator for inclusion in a clinical trial across more than 12 EU participating countries. Aptuit’s client was dealing with an Investigative Medicinal Product (IMP) manufactured in the United States and an EU-sourced comparator. By Aptuit, Inc.
94. Article: Improving Pharmaceutical Manufacturing Regulatory Risk 3/15/2010

    Pharmaceutical manufacturers must manage regulatory risk to ensure products are developed and produced in manner consistent with organizational goals and strategic objectives. Ongoing operations and marketplace supply can be hindered if a producer is not keenly aware of the regulatory environment and potential risks of underperforming processes. Operational requirements for development of clinical supply may also be adversely affected when regulatory issues exist. Similarly, drug development may be hindered by poorly performing production processes for managing laboratory testing, facilities and systems, quality and packaging/labeling. By ACSYS, Inc.

95. Infrastructure Investments, Innovation Accelerate Biologics Development

    Keeping pace with the market dynamics transforming the biologics space requires a focus on innovation and access to the integrated resources necessary to support it.

96. Improving The Supply Of Single-Use Technologies

    The use of single-use technologies has been growing steadily over the past decade, but there are still challenges that remain. Explore potential solutions for single-use supply constraints.

97. Global Clinical Supply Solutions For Every Trial

    A reliable clinical supply chain strategy is as essential as a company’s discovery program. Seek a partner who can help guide a comprehensive  strategy and manage day-to-day activities.

98. Direct-To-Patient Services

    Thermo Fisher Scientific provides scalable, custom direct-to-patient services that ensure patients receive their medication with controlled and on time delivery.

99. Singota Solutions: Your CDMO Focused On Faster

    Do you need a CDMO that will fill the gaps in the drug development process and focus on getting patients the treatments they need faster? Our team of experts at Singota is here to collaborate with you, customizing our services to meet your needs and hit your milestones.

100. Leading Critical Biological Material Management

     Ensure the integrity of your valuable material – from collection and storage through delivery to patient – with customized, end-to-end supply chain management solutions.